 Orgenesis Inc NASDAQ:ORGS FRA:45O announced that enrollment has commenced for a clinical trial using the companys Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Special Surgery HSS in New York. The Phase 2 trial, supported by the National Stem Cell Foundation and an Orthopedic Research and Education Foundation grant, will evaluate the safety and efficacy of autologous stromal and vascular fraction cells SVF that are injected after surgical rotator cuff repair. 